SABS vs. FBIO, CRIS, BOLT, MTEM, AMGN, GILD, VRTX, REGN, ALNY, and BIIB
Should you be buying SAB Biotherapeutics stock or one of its competitors? The main competitors of SAB Biotherapeutics include Fortress Biotech (FBIO), Curis (CRIS), Bolt Biotherapeutics (BOLT), Molecular Templates (MTEM), Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), and Biogen (BIIB). These companies are all part of the "biotechnology" industry.
SAB Biotherapeutics vs.
SAB Biotherapeutics (NASDAQ:SABS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, community ranking, media sentiment, dividends, risk, profitability and institutional ownership.
7.8% of SAB Biotherapeutics shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 26.5% of SAB Biotherapeutics shares are held by insiders. Comparatively, 33.4% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
SAB Biotherapeutics has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.
SAB Biotherapeutics currently has a consensus price target of $12.20, indicating a potential upside of 555.91%. Fortress Biotech has a consensus price target of $21.00, indicating a potential upside of 1,113.87%. Given Fortress Biotech's higher possible upside, analysts plainly believe Fortress Biotech is more favorable than SAB Biotherapeutics.
Fortress Biotech received 295 more outperform votes than SAB Biotherapeutics when rated by MarketBeat users. However, 84.62% of users gave SAB Biotherapeutics an outperform vote while only 63.69% of users gave Fortress Biotech an outperform vote.
In the previous week, SAB Biotherapeutics had 7 more articles in the media than Fortress Biotech. MarketBeat recorded 10 mentions for SAB Biotherapeutics and 3 mentions for Fortress Biotech. SAB Biotherapeutics' average media sentiment score of 0.74 beat Fortress Biotech's score of -0.22 indicating that SAB Biotherapeutics is being referred to more favorably in the media.
SAB Biotherapeutics has higher earnings, but lower revenue than Fortress Biotech. Fortress Biotech is trading at a lower price-to-earnings ratio than SAB Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Fortress Biotech has a net margin of -84.53% compared to SAB Biotherapeutics' net margin of -1,450.14%. Fortress Biotech's return on equity of 0.00% beat SAB Biotherapeutics' return on equity.
Summary
Fortress Biotech beats SAB Biotherapeutics on 10 of the 17 factors compared between the two stocks.
Get SAB Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SABS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
SAB Biotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:SABS) was last updated on 5/22/2025 by MarketBeat.com Staff